Anzeige
Mehr »
Dienstag, 30.06.2026 - Börsentäglich über 12.000 News
China kontrolliert Seltene Erden - Brasilien könnte die Antwort sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
399 Leser
Artikel bewerten:
(2)

Osteotec Secures Exclusive UK Distribution Agreement with Stratus Medical to Expand Access to Advanced RF Pain Management Technologies

NEWBURY, England, April 16, 2026 /PRNewswire/ -- Osteotec, the market leading manufacturer and distributor of specialised medical devices, has entered into an exclusive distribution agreement with Stratus Medical to supply its portfolio of radiofrequency (RF) technologies for pain management across the United Kingdom.

Headquartered in Magnolia, Texas, Stratus Medical focuses on advancing interventional pain therapies designed to alleviate chronic pain and improve patient quality of life. Under the agreement, Osteotec will distribute the company's flagship NIMBUS RF Multitined Expandable Electrode alongside additional RF solutions from its portfolio.

The NIMBUS device is engineered to create a large-volume lesion during radiofrequency ablation procedures, supporting physicians in delivering sustained pain relief while maintaining procedural efficiency. Its expandable multitined design is intended to simplify positioning and optimise treatment coverage, addressing a recognised clinical demand for reliable, cost-effective ablation technology.

This partnership represents a strategic addition to Osteotec's expanding portfolio of advanced interventional and surgical solutions, strengthening the breadth of technologies available to clinicians and reinforcing the company's commitment to enabling improved patient outcomes through innovation.

Dean Stockwell, Sales and Marketing Director at Osteotec, said: "Securing exclusive distribution rights for Stratus Medical's RF technologies reflects our ongoing focus on bringing clinically meaningful innovation to healthcare providers. These solutions broaden the therapeutic options available to pain specialists and surgeons across the UK, supporting procedural precision, workflow efficiency, and ultimately better outcomes for patients living with chronic pain."

The addition of Stratus Medical's RF portfolio further reinforces Osteotec's role as a trusted partner to clinicians seeking advanced technologies that support improved procedural outcomes.

"Partnering with Osteotec provides us with an experienced and highly respected commercial platform to expand access to our RF technologies," said Will Pankey, Vice President of Sales at Stratus Medical. "Their established relationships within both public and private healthcare settings make them an ideal partner to support adoption of our solutions and ensure physicians can deliver advanced pain management therapies to more patients."

About Osteotec

Osteotec is a manufacturer and distributor of medical devices headquartered in Newbury, UK, with offices in Dublin and Malmö. Established in 1993, Osteotec has been supplying into the public and private hospitals for the past 33 years.

Osteotec manufactures and distributes the Osteotec Silicone Finger, ChiroKlip and the Concentric Bone Graft System and is a distributor for world-leading orthopaedic partners including Highridge Medical, SI-BONE, TriMed, Enovis and Cerapedics.

Logo: https://mma.prnewswire.com/media/2958361/Osteotec_Logo.jpg

Media Contact:
Harriet Bawden
Marketing Manager
mkt@osteotec.com
020 3011 5574

For more information, visit www.osteotec.com.

About Stratus Medical

Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, Houston Business Journal's Top 300 Private Companies, and Fortune's America's Most Innovative Companies.

The Company's foundational NIMBUS technology has rapidly gained market share in the US and other countries due to its ease of use, reduced procedure times, and large volume lesion providing sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas.

Media Contact:
Cody Jorgensen
Marketing Communications
346-703-0642
cody@stratusmedical.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/osteotec-secures-exclusive-uk-distribution-agreement-with-stratus-medical-to-expand-access-to-advanced-rf-pain-management-technologies-302744832.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.